We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Abcuro is developing a new generation of immunomodulatory therapeutics for treating both autoimmunity and cancer. The company uses proprietary analysis of transcriptome data from human disease to target key compartments of the immune system.
Abcuro was launched in 2016 and to date it has raised over $10M to advance two functionally differentiated therapeutic programs that target KLRG1, an inhibitory receptor on T and NK cells. Abcuro’s autoimmunity program is under development for inclusion body myositis (IBM), primary biliary cholangitis (PBC) and other T cell driven autoimmunity indications including rare forms of leukemia.
Abcuro's immuno-oncology program is being developed for solid tumors via a biomarker based indication selection strategy.
Both programs have completed candidate selection and are now in pre-clinical development.